Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

LFWDAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.83+ 1.35%S&P 500 · SPY770.41+ 0.66%Dow Jones · DIA523.54+ 0.11%Russell 2000 · IWM280.14+ 1.14%

Lifeward’s ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study
Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia ReWalk was used for a median of 33 months, with no reported falls or exoskeleton-related fractures during the observation period; participants maintained 3,000+ steps per month, demonstrating sustained real-world utilization Participants reported high satisfaction including improvements in quality of life, mental health, bowel and bladder management, as well as less pain Long-t
Yahoo08:0013 Days AgoLFWD

04:00Oct 141 Story

Lifeward Announces Publication Of Long-Term Study On User Experience Of Its ReWalk Personal Exoskeleton In 'Spinal Cord Series And Cases'
Publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of the ReWalk® Personal Exoskeleton in individuals
Benzinga04:20LFWD

12:00Oct 81 Story

Lifeward Informed By Rami Aviram That He Will Not Assume CFO Role; Josh Hexter To Continue As Interim Principal Financial Officer, Principal Accounting Officer
https://www.sec.gov/ix?doc=/Archives/edgar/data/1607962/000117891326004746/zk2636213.htm
Benzinga12:37LFWD

04:00-09:00Sep 152 Stories

Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq
Yahoo08:00LFWD
Lifeward Announces Publication Of Researcher-Led Peer-Reviewed Study Showing Potential For Individuals With Chronic Spinal Cord Injury To Use Personal Exoskeleton To Perform Everyday Activities
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use ReWalk users with chronic spinal cord injury were able to perform everyday kitchen
Benzinga04:05LFWD

11:00Sep 111 Story

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
Oramed Pharmaceuticals holds as it shifts to strategic investments; strong returns from Alpha Tau, Lifeward & Scilex, but risks loom. Click for an ORMP update.
SeekingAlpha11:53LFWD

08:00Sep 81 Story

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website. The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, levera
Yahoo08:30LFWD

05:00Aug 141 Story

Lifeward Q2 Adj. EPS $(1.46) Misses $(1.34) Estimate, Sales $6.623M Beat $6.530M Estimate
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.34) by 8.96 percent. This is a 61.07 percent increase over losses of $(3.75) per share from the
Benzinga05:18LFWD

04:00Aug 51 Story

Lifeward Launches Six-Mointh Pilot Program With Ottobock Care To Enable Greater Patient Access To Its ReWalk 7 Personal Exoskeleton
The agreement brings together Lifeward’s advanced personal exoskeleton technology and Ottobock Care’s established clinical expertise and regional patient care infrastructure. Through the pilot, the companies intend to
Benzinga04:04LFWD